All In Biotech

Drug Trial Radar · NCT06880081

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

A Phase 1b, Open-label, Single-arm, Dose-escalation Study of PN20 in Patients With Primary Immune Thrombocytopenia (ITP)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Mar 7, 2025

Primary completion

Feb 14, 2026

Study completion Feb 14, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 treatment? Participants will * Receive one subcutaneous injection of PN20 according to weight; * Visit the clinic for assessment.

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

  • PN20 treatmentDrug

    Three dose cohorts, single dose, subcutaneous injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event (AE)Time frame: Treatment and post-treatment follow-up period (28 days after a single dose)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jining First People's Hospital

    Jining, Shandong, China

  • Hematology Hospital of Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.